NorthWest Biotherapeutics Inc (NWBO)

[CogDiss 1188X]

Not sure how these two rGBM arms compare with patients in the phase 3 trial in the control arm who recurred, then crossed over, other than the two arms outside the trial had more aggressive disease.
Not seeing evidence of 2nd surgeries — does it mean the vaccine was made from the primary tumor?

Does a 5 month extension in survival for the two rGBM arms raise the specter of confounding in a more tangible way or is this old news? (Probably should have asked this first, lol)